Preparation, Characterization and Evaluation of Ramipril Loaded Solid Lipid Nanoparticles for Improved Bioavailability

Abstract

Purpose: Ramipril is a potential antihypertensive drug employed in the management of hypertension and its oral bioavailability 28%. The intent of the work to evolve solid lipid nanoparticles of ramipril for enhancement of bioavailability. Methods: The SLNs of ramipril were developed by hot homogenization followed by ultrasonication technique. Lipids are dynasan 114, dynasan 116, dynasan 114, imwitor 900 P. Non inonic surfactants are poloxamer 188, polysorbate 80 and lipoid E 80 act as an amphoteric stabilizing agent is used to synthesize solid lipid nanoparticles of sumatriptan succinate. Results: Developed ramipril SLNs have shown the mean size of particles are 234-412 nm, Zeta potential values varied from -18.4 ± 0.782 to -42.2 ± 1.571 mV which indicated stability of developed ramipril solid lipid nanoprticles. Entrapment efficiency of formulations found between 94% and 99%. SLNs of ramipril were established likely spherical with a lustrous exterior, as examine making do with scanning electron microscope (SEM). The compatibility of drug with excipients was ascertained through differential scanning calorimetry (DSC). The bioavailability research considerations were carried out on male wistar rats, the innovative preparation of ramipril SLNs and coarse suspension administered by oral route. Conclusion: Relative bioavailability of developed formulation of SLNs of dynasan 114 and combination of poloxamer 188 and polysorbate 80 ramipril (F9) was increased by 1.35 times differentiated with the reference standard coarse suspension.